[1-glutamine and dipropylacetic acid as subsidiary psychotropic agents in the treatment of psychiatric in-patients. Effect on the neuroleptic consumption].
In a division of the neuropsychiatric hospital of Racconigi, with acute and chronic inpatients, the use of 1-glutamine and N-dipropylacetic acid as subsidiary psychodrugs, after one year follow-up, showed to have reduced the whole administration of neuroleptics, without diminishing the therapeutic efficacity. This administration, during the four sampler months (December, March, June and September), face with the sames of the preceding year, has been lesser than 29,04% (lesser than 38,21%, if we take into consideration the last two months). Such result has been confirmed by a corresponding diminution of orphenadrine, the drug used to counteract the neuroleptic syndrome, which during the last two months considered in this research, respectively subsided of 28,57% and 36,36%.
D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D005973:Glutamine / Q000627:therapeutic use*; D006801:Humans; D014149:Tranquilizing Agents / Q000008:administration & dosage*; D014631:Valerates / Q000627:therapeutic use*; D014635:Valproic Acid / Q000627:therapeutic use*
D014149:Tranquilizing Agents; D014631:Valerates; D005973:Glutamine; D014635:Valproic Acid
1-glutamine et acide dipropylacétique comme psychotropes subsidiaires dans le traitement des malades psychiatriques hospitalisés. Effets sur la consommation de neuroleptiques.